Systemic Corticosteroids Are Safe for Treating Gout in Patients with Atrial Fibrillation and HFrEF
Short-term, low-dose systemic corticosteroids are a safe and appropriate option for treating acute gout in patients with both atrial fibrillation and heart failure with reduced ejection fraction, particularly when NSAIDs and colchicine are contraindicated or not tolerated.
Rationale for Corticosteroid Use in This Population
Why NSAIDs Must Be Avoided
- NSAIDs are contraindicated in HFrEF because they increase the risk of heart failure worsening and HF hospitalization 1.
- All NSAIDs, not just selective COX-2 inhibitors, carry cardiovascular risk and should be avoided in patients with underlying cardiac disease 2, 3.
- In patients with decompensated HF and AF, intravenous nondihydropyridine calcium channel antagonists may exacerbate hemodynamic compromise 4.
Corticosteroid Safety Profile
- Short-duration, low-dose glucocorticoids are efficacious and may be safe for acute gout flares in patients with cardiovascular disease or heart failure 2.
- Systemic corticosteroids did not report serious adverse effects when used short-term for gout treatment 5.
- The key safety consideration is dose and duration: high-dose corticosteroid use (>7.5 mg prednisone equivalents daily) is associated with increased risk of new-onset atrial fibrillation (OR 6.07), while low-intermediate doses (<7.5 mg) are not significantly associated with AF risk (OR 1.42) 6.
Recommended Treatment Approach
First-Line: Colchicine
- Colchicine is considered safe and potentially reduces the risk of myocardial infarction in patients with cardiovascular disease 2.
- Colchicine may be considered postoperatively to reduce AF after cardiac surgery 7.
- This should be the initial choice if tolerated and not contraindicated by renal function or drug interactions.
Second-Line: Low-Dose Corticosteroids
If colchicine cannot be tolerated or is contraindicated, use short-term, low-dose corticosteroids:
- Keep daily dose <7.5 mg prednisone equivalents to minimize AF risk 6.
- Limit duration to the shortest effective course (typically 5-7 days for acute gout).
- Monitor for fluid retention, which could exacerbate HF symptoms 2.
- Ensure the patient is on optimal guideline-directed medical therapy (GDMT) for HFrEF, including ACE inhibitors/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors 8, 9, 10.
Avoid These Options
- Do not use NSAIDs due to HF worsening risk 1, 2.
- Avoid high-dose corticosteroids (>7.5 mg prednisone equivalents daily) due to significantly increased AF risk 6.
- IL-1 inhibitors (canakinumab, anakinra) are limited by high cost, risk of serious infection, and modest clinical benefit, though they may be considered in refractory cases 2.
Critical Monitoring Parameters
- Watch for fluid retention and weight gain, which could precipitate HF decompensation 2.
- Monitor heart rate control in AF patients, ensuring beta-blockers or other rate-control agents remain optimized 7.
- Assess for hyperglycemia, particularly in diabetic patients, as corticosteroids can worsen glucose control.
- Ensure continuation of HFrEF GDMT during acute gout treatment, as these medications should not be interrupted unless hemodynamic instability occurs 1, 10.
Long-Term Urate-Lowering Therapy Considerations
- Allopurinol should be considered first-line for long-term urate-lowering therapy given its safety and potential for reducing cardiovascular outcomes 2.
- Avoid febuxostat in this population due to increased risk of cardiovascular death and HF hospitalization 2.
- Probenecid is an alternative if allopurinol is not tolerated 2.